Watch for the proposed judgment within one week — if the remedy is a broad injunction restricting YUTREPIA sales entirely, the stock could face severe downside. If the remedy is limited to label removal of PH-ILD, the PAH indication remains intact, reducing the impact. The appeal process will be a multi-month catalyst.
Price Chart
Executive Summary
The District Court ruled that two of six patent claims asserted by United Therapeutics against Liquidia's YUTREPIA are valid and infringed, while the remaining four claims were invalidated. The parties must submit a proposed judgment within one week, and UTHR is seeking injunctive relief that could restrict YUTREPIA's market availability. Liquidia plans to appeal and will submit a label supplement to remove the PH-ILD indication, but the outcome and financial exposure remain uncertain.
Key Facts
- District Court ruled claims 1 and 14 of U.S. Patent No. 11,826,327 are valid and infringed by Liquidia.
- Four of six asserted claims were found invalid.
- Parties directed to submit a form of judgment specifying proposed remedies within one week.
- UTHR has asked the Court for injunctive relief that would restrict YUTREPIA's availability on the market.
- Liquidia intends to submit a supplement to YUTREPIA's NDA to remove PH-ILD from the label.
- Liquidia plans to pursue all available appellate options.
- Potential remedies range from removal of PH-ILD indication to broader product availability restrictions.
- YUTREPIA was approved in 2025 for PAH and PH-ILD.
Financial Impact
Financial exposure cannot be reasonably estimated per the filing; potential remedies range from label restriction to full market restriction on YUTREPIA, the company's lead product.
Risk Factors
- Injunctive relief could block YUTREPIA sales for one or both approved indications.
- Appeal outcomes are uncertain and could take years.
- Removal of PH-ILD indication would shrink the addressable market for YUTREPIA.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-112420 |
| Document: tm2626740d1_ex99-1.htm | 0001104659-26-112420 |
| Document: 0001104659-26-112420-index-headers.html | 0001104659-26-112420 |
| Document: 0001104659-26-112420-index.html | 0001104659-26-112420 |
| Document: 0001104659-26-112420.txt | 0001104659-26-112420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $44.26 (+30.42%) |
Oct 13, 2026 12d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $44.26 (+30.42%) |
Sep 30, 2026 25d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $44.26 (−58.15%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $44.26 (−35.50%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $44.26 (−35.50%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $44.26 (−37.97%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $44.26 (−37.01%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $44.26 (−43.82%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $44.26 (+43.82%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $44.26 (−49.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers